UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)

☒ [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~September~~ June 30, ~~2016~~2017

☐ [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to __________

Commission File Number 333-199589

DNA TESTING CENTERS, CORP.

(Exact name of registrant as specified in its charter)

Florida

applied for

(State or other jurisdiction of

incorporation or organization)

(IRS Employer

Identification No.)

2378 Parkhaven Blvd., Oakville, Ontario		L6H 0E7
(Address of principal executive offices)		(Zip Code)

+81 3-5764-3380 (Registrant’s telephone number, including area code) ~~N/A (Former name, former address and former fiscal year, if changed since last report)~~

~~Indicate~~N/A ~~by check mark whether the registrant~~ (1)Former ~~has~~name, ~~filed~~former ~~all~~address ~~reports~~and ~~required~~former tofiscal ~~be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports)~~year, ~~and~~if ~~(2)~~changed ~~has~~since ~~been~~last ~~subject to such filing requirements for the past 90 days. ☒ YES NO~~report)

Indicate by check mark whether the registrant (1) has ~~submitted~~filed ~~electronically~~all ~~and~~reports ~~posted on its corporate Web site, if any, every Interactive Data File~~ required to be ~~submitted~~filed ~~and~~by ~~posted~~Section ~~pursuant~~13 toor ~~Rule~~15(d) ~~405~~ of ~~Regulation~~the ~~S-T~~Securities Exchange ~~(§232.405~~Act of ~~this~~1934 ~~chapter)~~ during the preceding 12 months (or for such shorter period that the registrant was required to ~~submit~~file such reports), and ~~post~~(2) has been subject to such ~~files)~~filing requirements for the past 90 days. ☒[X] YES ☐[ ] NO

Indicate by check mark whether the registrant ishas asubmitted ~~large~~electronically ~~accelerated~~and ~~filer,~~posted anon ~~accelerated~~its ~~filer,~~corporate aWeb ~~non-accelerated~~site, ~~filer~~if any, orevery aInteractive Data ~~small~~File ~~reporting~~required ~~company.~~to ~~See~~be ~~the~~submitted ~~definitions~~and ~~of “large~~posted ~~accelerated~~pursuant ~~filer”,“accelerated~~to ~~filer” and “smaller~~Rule ~~reporting~~405 ~~company” in~~of ~~Rule~~Regulation ~~12b~~S-2T (§232.405 of this chapter) during the preceding ~~Exchange~~12 ~~Act~~months (or for such shorter period that the registrant was required to submit and post such files). [X] YES [ ] NO

1Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a small reporting company. See the definitions of “large accelerated filer”,”accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐[ ] Accelerated filer ☐[ ] Non-accelerated filer ☐[ ] Smaller reporting company ☒[X] (Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) ☐[ ] YES ☒[X] NO

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Check whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Exchange Act after the distribution of securities under a plan confirmed by a court. ☐[ ] YES ☐[ ] NO

APPLICABLE ONLY TO CORPORATE ISSUERS

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

21,496,404 common shares issued and outstanding as of ~~November~~June 304, ~~2016~~2019.

TABLE OF CONTENTS

~~PAGE~~ PART I -– FINANCIAL INFORMATION 43 Item 1. Financial Statements 43 Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 105 Item 3. Quantitative and Qualitative Disclosures About Market Risk 2214 Item 4. Controls and Procedures 2214 PART II-- – OTHER INFORMATION 2415 Item 1. Legal Proceedings 2415 Item 1A. Risk Factors 2415 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 2415 Item 3. Defaults Upon Senior Securities 2415 Item 4. Mine Safety Disclosures 2415 Item 5. Other Information 2415 Item 6. Exhibits 2516

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

Our ~~consolidated~~ unaudited interim consolidated financial statements for the three and ~~nine~~six month periods ended ~~September~~June 30, ~~2016~~2017 form part of this quarterly report. They are stated in United States Dollars (US$) and are prepared in accordance with United States generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X.

DNA Testing Centers Corp.
Consolidated Balance Sheets
(Unaudited)
ASSETS
		September 30,	December 31,
		2016	2015
Current Assets
	Cash	3,034	207
	Accounts Receivable	594	-
	Notes Receivable	4,631	154
	Total Current Assets	8,259	361
	Property and Equipment (net)	4,489	4,895
	Total Assets	12,748	5,256
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current Liabilities
	Accounts Payable	1,115	918
	Notes Payable, related party	61,184	5,780
	Total Current Liabilities	62,299	6,698
Stockholders’ Deficit
Preferred Stock, $0.0001 par value, 10,000.000
shares authorized, 0 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively
	Common Stock, $0.0001 par value, 49,000,000
	shares authorized, 21,469,404 and 21,146,404
	issued
	and outstanding at September 30, 2016 and
	December
	31, 2015, respectively	2,149	2,114
	Additional Paid in Capital	221,318	168,853
	Accumulated Deficit	(261,166)	(161,995)
	Other Comprehensive Loss	(11,852)	(10,414)
	Total Stockholders' Deficit	(49,551)	(1,442)
	Total Liabilities and Stockholders' Deficit	12,748	5,256
The accompanying notes are an integral part of these consolidated unaudited financial statements

DNA TESTING CENTERS, CORP.

5Condensed Consolidated Financial Statements

		DNA Testing Centers Corp.
Consolidated Statements of Operations and Other Comprehensive Income (loss)
	Three and Nine Months Ended September 30, 2016 and 2015 (Unaudited)
		Three Months Ended	Three Months Ended	Nine Months Ended	Nine Months Ended
		September 30, 2016	September 30, 2015	September 30, 2016	September 30, 2015
Revenue		11,503	4,564	20,854	14,964
Operating Expenses:
Testing Fees		12,626	16,827	37,440	33,650
Other Operating Expenses		3,465	13,201	30,085	79,694
Stock Based Compensation		-	-	52,500	-
Net Operating Expenses		16,091	30,028	120,025	113,345
Net Operating Income Before Taxes		(4,588)	(25,465)	(99,171)	(98,381)
Income Taxes		-	-	-	-
Net (loss)		(4,588)	(25,465)	(99,171)	(98,381)
Other Comprehensive (loss):
Foreign Currency Exchange Adjustment		792	(1,784)	(1,438)	(7,233)
Total Comprehensive Income (loss)		(3,796)	(27,249)	(100,609)	(105,614)
Net Income Per Common Share- Basic and Diluted		(0.00)	(0.00)	(0.00)	(0.00)
Weighted Average Common Shares Outstanding - Basic and Diluted		21,496,404	20,495,077	21,283,583	20,495,077

June 30, 2017

~~The~~(Expressed in ~~accompanying~~U.S. ~~notes are an integral part of these consolidated unaudited financial statements~~dollars)

6(unaudited)

DNA Testing Centers Corp. Consolidated Statement of Cash Flow Nine Months Ended September 30, 2016 and 2015 (Unaudited)

	Index

Condensed Consolidated Balance Sheets	F–1
Condensed Consolidated Statements of Operations and Comprehensive Loss	F–2
Condensed Consolidated Statements of Cash Flows	F–3
Notes to the Condensed Consolidated Financial Statements	F–4

		September 30, 2016	September 30, 2015
	OPERATING ACTIVITIES
	Net (Loss)	(99,171)	(98,381)
	Adjustments to reconcile net income
	to net cash provided by (used in) operations:
	Stock based compensation	52,500	-
	Bad debt expense	-	2
	Depreciation	406	-
	Changes in operating assets and liabilities:
	Accounts receivable	(594)	-
	Loan receivable	(4,477)	25
	Accounts payable	197	634
	Net cash provided by (used in) Operating Activities	(51,139)	(97,720)
	FINANCING ACTIVITIES
	Share capital issuance	-	53,177
	Proceed from note payable, related party	55,404	-
	Repayment on note payable, related party	-	(4,310)
	Net cash provided by (used in) Financing Activities	55,404	48,867
	Net Effect of Foreign currency exchange adjustment	(1,438)	(7,235)
	Net cash increase (decrease) for period	2,827	(56,088)
	Cash (overdraft) at beginning of period	207	65,083
	Cash (overdraft) at end of period	3,034	8,995
	Interest paid	-	-
	Taxes paid	-	-
The accompanying notes are an integral part of these consolidated unaudited financial statements

7DNA TESTING CENTERS, CORP.

~~DNA~~Condensed Consolidated ~~Testing~~Balance ~~Centers, Corp.~~Sheets

~~Notes~~(Expressed in toU.S. ~~Consolidated Unaudited Financial Statements~~dollars)

For the Period Ended September 30, 2016

	June 30, 2017 $			December 31, 2016 $
	(unaudited)

ASSETS

Current Assets

Cash		7,505			3,778
Accounts receivable		2,244			2,410

Total current assets		9,749			6,188

Property and equipment (Note 3)		3,712			3,820
Total Assets		13,461			10,008

LIABILITIES AND STOCKHOLDERS’ DEFICIT

Current Liabilities

Accounts payable and accrued liabilities		22,569			30,675
Due to related parties (Note 4)		105,874			88,866

Total Liabilities		128,443			119,541

Going Concern (Note 1)
Subsequent Events (Note 5)

Stockholder’s Deficit

Preferred stock, $0.0001 par value, 10,000,000 shares authorized, nil shares issued and outstanding		–			–
Common stock, 1,000,000,000 shares authorized, $0.0001 par value 21,496,404 shares issued and outstanding		2,149			2,149
Additional paid-in capital		221,318			221,318
Accumulated other comprehensive loss		(12,207	)		(9,718	)
Deficit		(326,242	)		(323,282	)

Total Stockholder’s Deficit		(114,982	)		(109,533	)

Total Liabilities and Stockholder’s Deficit		13,461			10,008

~~NOTE~~(The accompanying 1notes –are ~~DESCRIPTION~~an OFintegral ~~BUSINESS~~part ~~AND~~of ~~BASIS~~these OFcondensed ~~PRESENTATION~~consolidated financial statements)

~~Description of Business~~F-1

DNA TESTING ~~Testing Centers~~CENTERS, ~~Corp~~CORP. (the “Company”) was incorporated in Florida on July 3, 2014. On July 3, 2014, the company acquired DNA Testing Centers of Canada Ltd. DNA Testing Centers of Canada Ltd. performs testing related to analyzing and monitoring an individual’s genetic makeup. The acquisition will be treated consolidated as an entity under common control.

~~Basis~~Condensed Consolidated Statements of ~~presentation~~Operations and Comprehensive Income (Loss)

~~The accompanying consolidated financial statements of DNA Testing Centers, Corp.~~ (~~the “Company,” “we” or “our”) have been prepared~~ Expressed in ~~accordance with accounting principles generally accepted in the United States of America~~U.S. dollars)

In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the periods presented have been reflected herein. (unaudited)

Consolidation of Subsidiaries

	Three Months Ended June 30, 2017 $			Three Months Ended June 30, 2016 $			Six Months Ended June 30, 2017 $			Six Months Ended June 30, 2016 $
Revenue		16,759			5,871			32,476			9,351
Direct costs		4,796			3,596			6,643			6,292
Gross Profit		11,963			2,275			25,833			3,059

Expenses

Advertising and promotion		1,173			2,355			1,512			3,849
Depreciation		(2	)		87			232			209
Bad debts		2,045			–			2,687			–
Consulting fees		44			62,302			151			71,021
Office and miscellaneous		1,782			3,970			4,885			6,526
Professional fees		2,421			10,613			4,667			13,780
Rent (Note 4)		2,230			71			4,496			2,257
Salaries		4,175			–			10,163			–

Total Expenses		13,868			79,398			28,793			97,642

Net Loss for the Period		(1,905	)		(77,123	)		(2,960	)		(94,583	)
Other Comprehensive Loss

Foreign currency translation loss		(1,747	)		(828	)		(2,489	)		(2,230	)
Comprehensive Loss for the Period		(3,652	)		(77,951	)		(5,449	)		(96,813	)

Loss Per Share, Basic and Diluted		–			–			–			–

Weighted Average Shares Outstanding		21,496,404			21,175,410			21,496,404			21,175,250

~~Our~~(The accompanying ~~consolidated~~notes ~~financial~~are ~~statements~~an ~~include~~integral ~~the~~part ~~accounts~~ of ~~DNA~~these ~~Testing~~condensed ~~Centers~~consolidated offinancial ~~Canada Ltd., our wholly-owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation.~~statements)

~~NOTE~~ F-2 ~~– SIGNIFICANT ACCOUNTING POLICIES~~

~~Going~~DNA TESTING ~~concern-The accompanying financial statements have been prepared in conformity with generally accepted accounting principles~~CENTERS, ~~which contemplate continuation of the Company as a going concern~~CORP. However, the Company has accumulated deficit of $261,166 as of September 30, 2016, and realized negative cash used in operations totaling $51,139 for the period ended September 30, 2016.The Company currently has limited liquidity, and has not completed its efforts to establish a stabilized source of revenues sufficient to cover operating costs over an extended period of time. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

8Condensed Consolidated Statements of Cash Flows

~~Management~~(Expressed in ~~anticipates that the Company will be dependent, for the near future, on additional investment capital to fund operating expenses~~U. ~~The Company intends to position itself so that it may be able to raise additional funds through the capital markets~~S. ~~In light of management’s efforts, there are no assurances that the Company will be successful in this or any of its endeavors or become financially viable and continue as a going concern.~~dollars)

Recently issued accounting pronouncements – We do not expect the adoption of recently issued accounting pronouncements to have a significant impact on our results of operations, financial position or cash flow.(unaudited)

NOTE 3 - CONCENTRATION

	Six Months Ended June 30, 2017 $			Six Months Ended June 30, 2016 $

Operating Activities

Net loss		(2,960	)		(94,583	)

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		232			209
Bad debts expense		2,687			–
Stock-based compensation		–			52,500

Changes in operating assets and liabilities:
Accounts receivable		(2,521	)		(182	)
Other receivable		–			(10	)
Accounts payable and accrued liabilities		(8,106	)		(255	)
Due to related parties		4,496

Net Cash Used In Operating Activities		(6,172	)		(42,321	)

Financing Activities

Proceeds from related parties		9,327			47,213

Net Cash Provided By Financing Activities		9,327			47,213

Effect of foreign exchange rate changes on cash		572			(2,196	)

Change in Cash		3,727			2,696

Cash, Beginning of Period		3,778			207

Cash, End of Period		7,505			2,903

Supplemental Disclosures:

Interest paid		–			–
Income taxes paid		–			–

~~All~~(The accompanying ofnotes ~~the~~are ~~Company’s~~an ~~operations~~integral ~~are~~part ~~located~~of inthese ~~Canada.~~condensed consolidated financial statements)

~~NOTE 4 – RELATED PARTY TRANSACTIONS~~F-3

~~During~~DNA TESTING ~~the period ended September 30~~CENTERS, ~~2016, we borrowed $55,404 (December 31, 2015 - $5,780) from a related party for working capital and repaid $ Nil of this balance (December 31, 2015 - $4,310)~~CORP. ~~As of September 30, 2016 and December 31, 2015, the balance owed is $61,184 and $5,780, respectively.~~

The Company operates as a full-time business and has one full time employee, office rent and other ongoing obligations. It shares the expenses with several sister companies, all with common ownership. Such expenses are allocated Notes to the ~~company~~Consolidated ~~based~~Condensed onFinancial ~~the share of use.~~Statements

~~NOTE~~June 30, ~~5 – SHAREHOLDERS’ EQUITY~~2017

~~On June 15, 2016, an aggregate of 350,000 shares at $0.15 per share~~ (~~for an aggregate of $52,500) were issued~~ Expressed in ~~exchange of two shareholders entering into certain agreements to restrict the sale shares with the Company~~U.S. dollars)

9(unaudited)

~~Item 2~~1. ~~Management’s~~Nature ~~Discussion and Analysis~~ of ~~Financial~~Operations ~~Condition~~ and ~~Results~~Continuance of ~~Operations~~Business

~~FORWARD-LOOKING~~DNA Testing ~~STATEMENTS~~Centers, Corp. (the “Company”) was incorporated in Florida on July 3, 2014. On July 3, 2014, the Company acquired DNA Testing Centers of Canada Ltd. (“DNA Canada”). DNA Canada performs testing related to analyzing and monitoring an individual’s genetic makeup. The acquisition was treated consolidated as an entity under common control.

~~This~~The accompanying ~~quarterly~~condensed ~~report~~consolidated ~~contains forward-looking statements. These statements relate to future events or our future~~ financial ~~performance. In some cases, you can identify forward-looking~~ statements byof ~~terminology~~the ~~such~~Company ~~as “may”, “~~should”, ~~“expects”,~~be ~~“plans”,~~read ~~“anticipates”,~~in ~~“believes”,~~conjunction ~~“estimates”,~~with ~~“predicts”, “potential” or “continue” or~~ the ~~negative~~consolidated ~~of these terms or other comparable terminology. These~~ financial statements ~~are only predictions~~ and ~~involve~~accompanying ~~known~~notes ~~and~~filed ~~unknown~~with ~~risks,~~the ~~uncertainties~~U.S. Securities and ~~other~~Exchange ~~factors~~Commission ~~that~~in ~~may~~the ~~cause our or our industry~~Company’s ~~actual~~Annual ~~results,~~Report on ~~levels~~Form of10-K ~~activity,~~for ~~performance~~the orfiscal ~~achievements~~year toended beDecember ~~materially~~31, ~~different~~2016. ~~from~~In ~~any~~the ~~future~~opinion ~~results, levels~~ of ~~activity~~management, ~~performance or achievements expressed or implied by these forward-looking statements. Although we believe that~~ the ~~expectations~~accompanying ~~reflected~~condensed inconsolidated financial ~~the forward-looking~~ statements ~~are~~reflect ~~reasonable,~~all weadjustments ~~cannot guarantee future results, levels~~ of ~~activity,~~a ~~performance~~recurring ornature ~~achievements.~~considered ~~Except~~necessary asto ~~required~~present byfairly ~~applicable law, including~~ the ~~securities~~Company’s financial ~~laws~~position ofand the ~~United~~results ~~States,~~of weits dooperations ~~not~~and ~~intend~~its tocash ~~update~~flows ~~any~~for of the ~~forward-looking~~periods ~~statements to conform these statements to actual results~~shown.

~~Our~~The preparation ~~consolidated~~of ~~unaudited~~these condensed consolidated financial statements ~~are stated~~ in ~~United~~accordance ~~States~~with ~~Dollars~~accounting ~~(US$)~~principles ~~and~~generally ~~are~~accepted ~~prepared~~ in the ~~accordance with~~ United States ~~Generally~~requires ~~Accepted~~management ~~Accounting~~to ~~Principles.~~make ~~The~~estimates ~~following discussion should be read in conjunction with our financial statements~~ and ~~the~~assumptions ~~related notes~~ that ~~appear~~affect ~~elsewhere~~the inamounts ~~this quarterly report~~reported. ~~The~~Actual ~~following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual~~ results could differ materially from those ~~discussed in the forward-looking statements~~estimates. ~~Factors~~The ~~that~~results ~~could~~of ~~cause~~operations orand ~~contribute~~cash toflows ~~such~~for ~~differences~~the ~~include,~~periods ~~but~~shown are not ~~limited~~necessarily ~~to,~~indicative of ~~those~~the ~~discussed~~results ~~below~~to ~~and~~be ~~elsewhere~~expected infor ~~this~~the ~~quarterly~~full ~~report~~year.

~~Unless~~These condensed ~~otherwise~~consolidated ~~specified~~financial instatements ~~this~~have ~~quarterly~~been ~~report~~prepared on a going concern basis, ~~all~~which ~~dollar~~implies ~~amounts~~the ~~are~~Company ~~expressed~~will continue to realize its assets and discharge its liabilities in ~~United~~the ~~States~~normal ~~dollars~~course of business. The continuation of the Company as a going concern is dependent upon the continued financial support from its shareholders, the ability of the Company to obtain necessary equity financing to continue operations, and ~~all~~the ~~references~~attainment of profitable operations. As at June 30, 2017, the Company has an accumulated deficit of $326,242 and a working capital deficit of $118,694. The Company currently has limited liquidity, and has not completed its efforts to ~~“common~~establish ~~stock”~~a ~~refer~~stabilized source of revenues sufficient to ~~shares~~cover operating costs over an extended period of ~~our~~time. ~~common~~These ~~stock~~factors raise substantial doubt regarding the Company’s ability to continue as a going concern. These condensed consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

~~As used in this quarterly report, the terms “we”, “us”, “our” and “our company” mean DNA Testing Centers, Corp~~2. ~~and~~Significant ~~our~~Accounting ~~wholly owned subsidiary, DNA Testing Centers of Canada, Ltd., a company formed pursuant to the laws of Alberta, unless otherwise indicated.~~Policies

~~Corporate~~(a) ~~Overview~~Basis of Presentation

WeThese condensed ~~are~~consolidated ~~incorporated~~financial instatements ~~the~~and ~~State~~related ofnotes ~~Florida~~are onpresented ~~July~~in 3,accordance ~~2014~~with ~~and~~accounting ~~incorporated~~principles togenerally accepted ~~acquire~~in ~~our~~the ~~wholly~~United ~~owned~~States ~~subsidiary~~and ~~DNA~~are ~~Centers~~expressed ofin ~~Canada,~~U.S. ~~Ltd~~dollars., aThese ~~Canadian~~condensed ~~corporation~~consolidated ~~formed~~financial onstatements ~~April~~include 6,the accounts ~~2009,~~of tothe ~~distribute~~Company ~~DNA~~and ~~diagnostic~~its ~~testing~~wholly-owned ~~kits~~subsidiary, toDNA ~~consumers~~Canada. All inter-company accounts and ~~medical~~transactions ~~practitioners~~have inbeen ~~Canada~~eliminated on consolidation.

On(b) ~~July~~Comprehensive ~~3, 2014, we issued an aggregate of 19,999,998 or 6,666,666 common shares to:~~Loss

1Comprehensive loss consists of net loss and other related gains and losses affecting stockholders’ equity that are excluded from net income or loss. As at June 30, 2017 and 2016, comprehensive loss includes cumulative translation adjustments for changes in foreign currency exchange rates during the period.

~~7612176~~(c) ~~Canada Inc., a Canadian corporation, controlled by Dr. Barjinder Sohal, our chief executive officer, president and director,~~Reclassifications

2Certain of the prior year figures were reclassified to conform to the current year’s presentation.

~~7322640~~(d) ~~Canada~~Recent ~~Inc.~~Accounting ~~a Canadian corporation controlled by Dr. Nitan Arora, our vice president and director, and~~Pronouncements

3The Company has implemented all new accounting pronouncements that are in effect and that may impact its consolidated financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

~~7322747 Canada Inc. a Canadian corporation controlled by Navjot Nanda our secretary, treasurer and director,~~F-4

10DNA TESTING CENTERS, CORP.

InNotes to ~~exchange, we acquired 100% of~~ the ~~outstanding~~Consolidated ~~shares~~Condensed ofFinancial DNA Testing Centers of Canada, Ltd., which became our wholly-owned subsidiary. At the time of the acquisition, 7612176 Canada Inc., 7322640 Canada Inc. and 7322747 Canada Inc. each held 33.33% of DNA Centers of Canada, Ltd. representing 100% of its outstanding securities.Statements

~~Our principal executive office is located at 2378 Parkhaven Boulevard~~June 30, ~~Oakville, Ontario, L6H 0E7, Canada. Our telephone number is 1-866-863-5139. Our website is www.dnatestingcanada.com.~~2017

~~Our~~(Expressed in ~~Current~~U.S. ~~Business~~dollars)

~~We provide DNA testing kits directly to consumers and to health care practitioners. We distribute and ship our products only in Canada.~~(unaudited)

~~Our~~3. ~~operations~~Property ~~to date~~ and ~~those of our wholly owned subsidiary, DNA Testing Centers of Canada, Ltd., include:~~Equipment

		Cost $				Accumulated depreciation $				Foreign currency translation loss $				Net carrying Value June 30, 2017 $				Net carrying Value December 31, 2016 $
Medical equipment			5,440				1,048				680				3,712				3,820

~~development~~4. ofRelated ~~our~~Party ~~business plan;~~Transactions

(a) As at June 30, 2017, the Company owed $1,558 (December 31, 2016 – $1,558) and $1,926 (Cdn$2,500) (December 31, 2016 - $nil) to the Chief Executive Officer of the Company which is non-interest bearing, unsecured, and due on demand. (b) As at June 30, 2017, the Company owed $1,558 (December 31, 2016 – $1,558) and $77,991 (Cdn$101,249) (December 31, 2016 – $68,708 (Cdn$92,249)) to the Chief Financial Officer of the Company which are non-interest bearing, unsecured, and due on demand. (c) As at June 30, 2017, the Company owed $1,558 (December 31, 2016 – $1,558) to a director of the Company which is non-interest bearing, unsecured, and due on demand. (d) As at June 30, 2017, the Company owed $11,555 (Cdn$15,000) (December 31, 2016 – $6,704 (Cdn$9,000)) to a director of the Company which is non-interest bearing, unsecured, and due on demand. (e) As at June 30, 2017, the Company owed $5,800 (December 31, 2016 – $5,800) and $847 (Cdn$1,100) (2016 - $nil) to the spouse of a director of the Company which is non-interest bearing, unsecured, and due on demand. (f) As at June 30, 2017, the Company owed $3,081 (Cdn$4,000) (December 31, 2016 - $2,980 (Cdn$4,000)) to the spouse of a director of the Company which is non-interest bearing, unsecured, and due on demand. (g) During the six months ended June 30, 2017, the Company incurred $4,496 (2016 - $2,257) in rent to a director of the Company.

~~research~~5. ~~and~~Subsequent ~~development of DNA testing methods and technologies;~~Events

	(a)	On July 24, 2017, the Company received proceeds of $100,000 for 1,000,000 common shares at a price of $0.10 per common share to be issued.

	(b)	On January 29, 2018, the Company paid a shareholder of the Company a return of capital of $15,000.

~~locating suppliers for DNA testing kits;~~F-5

4Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

~~locating and reviewing potential labs to interpret our DNA testing kits;~~FORWARD-LOOKING STATEMENTS

5This quarterly report contains forward-looking statements. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expects”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

~~creating~~Our unaudited consolidated financial statements are stated in United States dollars (US$) and are prepared in accordance with United States generally accepted accounting principles. The following discussion should be read in conjunction with our ~~marketing~~consolidated financial ~~strategy;~~statements and the related notes that appear elsewhere in this quarterly report. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed below and elsewhere in this quarterly report.

6Unless otherwise specified in this quarterly report, all dollar amounts are expressed in United States dollars and all references to “common stock” refer to shares of our common stock.

~~developing~~As used ~~content~~in ~~for~~this quarterly report, the terms “we”, “us”, “our” ~~website~~and ~~that~~“our ~~describes~~company” mean DNA ~~technology~~Testing Centers, ~~the~~Corp. and our wholly owned subsidiary, DNA ~~testing~~Testing ~~process~~Centers ~~and~~of Canada, Ltd., a company formed pursuant to the ~~DNA~~laws ~~test~~of ~~kits~~Alberta, weunless ~~sell;~~otherwise ~~and~~indicated.

7.Corporate Overview

~~selling~~We are ~~our~~incorporated ~~DNA~~in ~~testing~~the ~~kits~~State toof ~~medical~~Florida ~~practitioners~~on ~~and~~July ~~directly~~3, 2014 to ~~consumers. DNA~~acquire ~~Testing~~our wholly owned subsidiary DNA Centers of Canada, Ltd., ~~commenced~~a Canadian ~~sales~~corporation offormed ~~its~~on ~~products~~April in6, ~~April~~2009, ofto ~~2010~~distribute DNA diagnostic testing kits to consumers and medical practitioners in Canada.

~~DNA~~On July ~~Testing Centers of Canada~~3, ~~Ltd.~~2014, ~~our~~we ~~wholly~~issued ~~owned~~an ~~subsidiary,~~aggregate ~~commenced sales~~ of ~~its products in April of 2010. To date~~19, ~~product sales were generated from our website and sold by phone order. Our customers pick up and pay for their purchases at our office location at 2378 Parkhaven Boulevard~~999,998 ~~Oakville,~~or ~~Ontario~~6, ~~L6H 0E7~~666,666 ~~Canada.~~common Weshares ~~do not use an outside sales force.~~to:

We1. ~~presently~~7612176 ~~offer~~Canada ~~our~~Inc., ~~paternity~~a ~~testing~~Canadian ~~kits~~corporation, ~~for~~controlled ~~purchase~~by onDr. Barjinder Sohal, our ~~website~~chief executive officer, president and director, 2. We7322640 ~~offer~~Canada ~~our~~Inc. ~~remaining~~a ~~test~~Canadian ~~kits~~corporation ~~for~~controlled ~~purchase~~by onDr. Nitan Arora, our ~~website~~vice ~~using~~president anand ~~online~~director, ~~shopping~~and ~~cart~~3. 7322747 Canada Inc. a Canadian corporation controlled by Navjot Nanda our secretary, treasurer and director,

~~Customer~~In exchange, ~~Price~~we ~~and~~acquired ~~Accuracy~~100% of ~~Our~~the outstanding shares of DNA ~~Test~~Testing ~~Kits~~Centers of Canada, Ltd., which became our wholly-owned subsidiary. At the time of the acquisition, 7612176 Canada Inc., 7322640 Canada Inc. and 7322747 Canada Inc. each held 33.33% of DNA Centers of Canada, Ltd. representing 100% of its outstanding securities.

As reflected in the chart below, all of our tests have an accuracy rate of 99.8% except for our prenatal gender test which is 98% effective. All of our tests are based upon a saliva sample. The most common reason for result errors in our tests is an insufficient saliva sample.5

11Our principal executive office is located at 2378 Parkhaven Boulevard, Oakville, Ontario, L6H 0E7, Canada. Our telephone number is 1-866-863-5139. Our website is www.dnatestingcanada.com.

~~The~~Our Current ~~cost per test kit for our DNA testing kits and accuracy of each kit is summarized below:~~Business

Type of Test	Price Per Kit
Prenatal Gender Test	$149.00
Paternity Tests - Informational	$94.00
Paternity Tests - Legal	$150.00
Kinship Test	$155.00
Ancestry DNA Testing	$250.00
Genetic Predisposition (Carrier, Drug, Health)	$249.00
Genetic Pred + Diet & Fitness as Bundle Test	$349.00
Carrier Testing	$300.00
Drug Response Testing	$300.00
Health Condition Testing	$300.00
Diet & Fitness Testing	$300.00

We provide DNA testing kits directly to consumers and to health care practitioners. We distribute and ship our products only in Canada.

Our operations to date and those of our wholly owned subsidiary, DNA Testing ~~Technologies~~Centers of Canada, Ltd., include:

~~DNA~~1. ~~testing~~development ~~generates~~of ~~genetic~~our ~~profile~~business ~~information~~plan; by2. ~~analyzing~~research anand ~~organism’s~~development ~~unique~~of ~~genetic~~DNA ~~identity~~testing methods and technologies; 3. ~~The~~ ~~process~~locating ofsuppliers ~~identifying~~for ~~unique~~DNA ~~variations~~testing inkits; a4. ~~genome~~locating isand ~~referred~~reviewing potential labs to asinterpret our DNA testing kits; 5. ~~DNA~~ ~~testing~~creating isour ~~the~~marketing ~~standard~~strategy; ~~method~~6. ~~used~~developing content for ~~forensic~~our ~~identification~~website that describes DNA technology, ~~ancestry~~the ~~tracing~~DNA testing process and the DNA test kits we sell; and 7. selling our DNA testing kits to ~~confirm~~medical ~~paternity~~practitioners and ~~other~~directly ~~family~~to ~~relationships~~consumers. DNA Testing Centers of Canada, Ltd., commenced sales of its products in April of 2010.

WeDNA Testing ~~provide~~Centers ~~two~~of ~~types~~Canada, Ltd., our wholly owned subsidiary, commenced sales of ~~DNA~~its ~~testing~~products in April of 2010. To date, product sales were generated from our website and sold by phone order. Our customers pick up and pay for their purchases at our office location at 2378 Parkhaven Boulevard, Oakville, Ontario, L6H 0E7, Canada. We do not use an outside sales force.

~~The~~We presently ~~first~~offer isour ~~composed~~paternity oftesting ~~ancestral~~kits ~~testing~~for ~~(both~~purchase ~~paternal~~on ~~and~~our ~~maternal),~~website. ~~paternity~~We ~~testing~~offer ~~(informational~~our ~~and~~remaining ~~legal),~~test ~~prenatal~~kits ~~gender~~for ~~testing,~~purchase ~~and~~on ~~twin~~our ~~diagnostic~~website using ~~testing~~an online shopping cart.

~~The~~Customer Price ~~second~~and ~~tests~~Accuracy ~~for~~of ~~disease~~Our ~~predisposition. These~~DNA ~~tests~~Test ~~can identify a person’s genetic risk for cancer, heart conditions, inherited conditions, nutrition, fitness response, and drug response to medication.~~Kits

AAs reflected ~~DNA~~in ~~profile~~the ~~can~~chart bebelow, ~~determined~~all ~~from~~of ~~any~~our ~~type~~tests have an accuracy rate of ~~biological~~99.8% ~~specimen~~except ~~containing~~for ~~nuclear~~our ~~DNA,~~prenatal ~~including~~gender ~~blood~~test orwhich is 98% effective. All of our tests are based upon a ~~tissue~~saliva sample,. ~~such~~The asmost acommon ~~cheek~~reason ~~swab~~for orresult errors in our tests is an insufficient saliva sample.

~~DNA~~The cost ~~testing~~per ~~currently~~test ~~used~~kit for ~~identity~~our ~~purposes examines specific sequences of~~ DNA ~~that~~testing ~~exhibit~~kits ~~variability~~and ~~between~~accuracy ~~different~~of ~~individuals. Our~~each ~~tests~~kit ~~use~~is ~~SNP~~summarized ~~genotyping, DNA sequencing and STR markers.~~below:

Type of Test	Price Per Kit
Prenatal Gender Test	$	149.00
Paternity Tests - Informational	$	94.00
Paternity Tests - Legal	$	150.00
Kinship Test	$	155.00
Ancestry DNA Testing	$	250.00
Genetic Predisposition (Carrier, Drug, Health)	$	249.00
Genetic Pred + Diet & Fitness as Bundle Test	$	349.00
Carrier Testing	$	300.00
Drug Response Testing	$	300.00
Health Condition Testing	$	300.00
Diet & Fitness Testing	$	300.00

~~SNP Genotyping~~6

ADNA Testing SNP is a Single Nucleotide Polymorphism. These are single base pairs in a genome that exhibit variation across the human population. There are two applications a SNP can be used for, one is whole genome association studies and the other is point mutation. In whole genome association studies, large amounts of data in the form of SNPs are gathered from a sample of people. Depending on what the target of the study is, associations can be made based on a person’s SNP profile. Here is a fictitious example: a person with an “A” base at position 765,659 on chromosome 11 has a 100 times higher likelihood of developing a rare form of cancer than a person with a “T” base. This is not a definitive diagnosis but can definitely be helpful information for the patient in terms of preventative care.Technologies

ADNA testing ~~SNP~~generates ~~marker~~genetic ~~can~~profile ~~also~~information ~~detect~~by aanalyzing ~~genetic~~an ~~disease~~organism’s ~~like~~unique ~~cystic~~genetic ~~fibrosis~~identity. In ~~this~~The ~~case~~process ~~the~~of ~~SNP~~identifying unique ~~(or~~variations 3in ~~base~~a ~~pairs~~genome inis ~~the~~referred ~~case~~to ofas ~~cystic~~DNA ~~fibrosis)~~testing. ~~will~~DNA ~~show~~testing ~~definitively~~is ifthe astandard ~~person~~method ~~has~~used ~~the~~for ~~disease~~forensic oridentification, ancestry ~~not. The~~tracing ~~association~~and isto ~~100%~~confirm paternity and other family relationships.

We provide two types of DNA ~~Sequencing~~testing.

InThe first ~~DNA~~is ~~sequencing,~~composed ~~300-500 base pair stretches~~ of ~~DNA~~ancestral ~~are~~testing ~~elucidated~~(both topaternal ~~show~~and amaternal), ~~more~~paternity ~~complete~~testing ~~picture. DNA~~(informational ~~sequencing~~and islegal), ~~helpful~~prenatal ingender testing, ~~determining~~and ~~genetic~~twin ~~disorders~~diagnostic ~~that SNP analysis alone cannot do~~testing. ~~DNA sequencing is also critical in the development of SNP assays.~~

~~STR~~The second ~~Markers~~tests for disease predisposition. These tests can identify a person’s genetic risk for cancer, heart conditions, inherited conditions, nutrition, fitness response, and drug response to medication.

A ~~short tandem repeat (“STR”) is a portion of~~ DNA inprofile ~~which~~can ~~small~~be ~~sequences~~determined ~~are~~from ~~repeated~~any atype ~~variable number~~ of ~~times. Typically,~~biological ~~there~~specimen ~~are~~containing 10nuclear ~~to 25 possible variations of a given human STR marker~~DNA, ~~with~~including ~~each~~blood ~~person having just one~~ or ~~two variations. By looking at~~ a ~~moderate~~tissue ~~number of STRs~~sample, such as a ~~DNA~~cheek ~~profile~~swab isor ~~determined that is virtually unique for each individual~~saliva. ~~STRs are the most common genetic markers used in the industry to determine identity in forensic, paternity and security applications.~~

DNA testing currently used for identity purposes examines specific sequences of DNA that exhibit variability between different individuals. Our ~~Products~~tests use SNP genotyping, DNA sequencing and STR markers.

~~We sell the following types of DNA test kits to medical practitioners and directly to consumers located in Canada:~~SNP Genotyping

~~Prenatal~~A SNP ~~Gender~~is ~~Test~~a Single Nucleotide Polymorphism. These are single base pairs in a genome that exhibit variation across the human population. There are two applications a SNP can be used for, one is whole genome association studies and the other is point mutation. In whole genome association studies, large amounts of data in the form of SNPs are gathered from a sample of people. Depending on what the target of the study is, associations can be made based on a person’s SNP profile. Here is a fictitious example: a person with an “A” base at position 765,659 on chromosome 11 has a 100 times higher likelihood of developing a rare form of cancer than a person with a “T” base. This is not a definitive diagnosis but can definitely be helpful information for the patient in terms of preventative care.

~~The~~A SNP ~~Prenatal~~marker ~~Gender~~can ~~Test~~also ~~determines~~detect ~~gender~~a ~~after~~genetic 7disease ~~weeks~~like ofcystic ~~gestation~~fibrosis. ~~This~~ ~~test~~In ~~works~~this bycase ~~looking~~the ~~for~~SNP a(or Y3 ~~chromosome~~base ~~within~~pairs in the ~~mother’s~~case ~~blood~~of cystic fibrosis) will show definitively if a person has the disease or not. The association is 100%.

~~Paternity Test – Informational~~DNA Sequencing

~~The~~In DNA ~~Paternity~~sequencing, ~~Test~~300-500 ~~uses~~base pair stretches of DNA are elucidated to show a ~~cheek~~more ~~swab~~complete ~~collected~~picture. ~~from~~DNA ~~both~~sequencing ~~the~~is ~~child~~helpful ~~and~~in determining ~~the~~genetic ~~alleged~~disorders ~~father~~that toSNP ~~determine~~analysis ~~parentage~~alone cannot do. DNA ~~Testing~~sequencing ~~Centers~~is ~~uses~~also acritical 15in ~~genetic~~the ~~marker~~development ~~analysis~~of SNP assays.

13STR Markers

~~Paternity~~A short ~~Test~~tandem -repeat ~~Legal~~(“STR”) is a portion of DNA in which small sequences are repeated a variable number of times. Typically, there are 10 to 25 possible variations of a given human STR marker, with each person having just one or two variations. By looking at a moderate number of STRs, a DNA profile is determined that is virtually unique for each individual. STRs are the most common genetic markers used in the industry to determine identity in forensic, paternity and security applications.

The Paternity Test uses a cheek swab collected from both the child and the alleged father to determine parentage. DNA Testing Centers uses a 15 genetic marker analysis. This test must be performed at a medical clinic and is designed to be used in legal proceedings to establish paternity.7

~~Kinship Testing~~Our Products

AWe sell ~~DNA kinship test determines~~ the ~~relationship~~following ~~between~~types ~~two~~of orDNA ~~more~~test ~~individuals~~kits to ~~assess~~medical anpractitioners ~~alleged~~and ~~relationship~~directly ~~such~~to asconsumers ~~full~~located orin ~~half siblings, grandparents and aunts or uncles~~Canada:

~~Ancestral~~Prenatal Gender ~~Origins Testing~~Test

The Prenatal ~~Ancestry~~Gender ~~test~~Test ~~provides~~determines angender ~~estimated~~after ~~percentage~~7 weeks of ~~ancestry~~gestation. ~~from~~This ~~four~~test ~~different~~works ~~population~~by ~~groups:~~looking ~~Indigenous~~for ~~American,~~a ~~European,~~Y ~~East~~chromosome ~~Asian~~within ~~and~~the ~~Sub-Saharan African~~mother’s blood.

~~Genetic~~Paternity Test ~~Predisposition~~– Informational

~~Genetic~~The Paternity ~~predisposition~~Test ~~testing~~uses ~~can~~a ~~identify~~cheek aswab ~~person’s~~collected ~~predisposition~~from ~~for~~both ~~over~~the 70child ~~health~~and ~~conditions~~the ~~based~~alleged ~~upon~~father ~~their~~to determine parentage. DNA Testing Centers uses a 15 genetic marker analysis.

~~Carrier~~ Paternity Test ~~Identification~~- Legal

~~Carrier~~The Paternity ~~test~~Test ~~identification~~uses ~~can~~a ~~identify~~cheek ~~individuals~~swab ~~who~~collected ~~carry~~from both the child and the alleged father to determine parentage. DNA Testing Centers uses a 15 genetic ~~disorder~~marker analysis. This test must be performed at a medical clinic and is designed to be used in legal proceedings to establish paternity.

~~Drug Response~~ Kinship Testing

~~Drug~~A DNA ~~response~~kinship ~~testing~~test ~~identifies~~determines ~~uses~~the arelationship ~~person’s~~between ~~DNA~~two toor ~~identify~~more ~~metabolism~~individuals ~~enzymes~~to ~~and~~assess ~~transporters~~an ~~that~~alleged ~~have~~relationship ~~been~~such ~~linked~~as tofull ~~harmful~~or half ~~reactions~~siblings, ~~with~~grandparents ~~common~~and ~~medical~~aunts ~~prescriptions~~or uncles.

~~The~~Ancestral Origins Testing ~~Process~~

~~Our~~The Ancestry ~~DNA~~ test ~~kits~~provides ~~include~~an ~~swabs~~estimated topercentage ~~collect a saliva sample, detailed instructions and pre-labeled packaging to send the sample to us. Upon receipt~~ of ~~the~~ancestry ~~sample,~~from itfour isdifferent ~~registered~~population ingroups: ~~our~~Indigenous database and sent to a third party laboratory to be interpreted. All tests are interpreted by either US laboratories accredited by CLIA and CAP or Canadian laboratories accredited by the Standard Council of Canada and CAP. After interpretationAmerican, ~~the laboratory delivers the test results to us by email. Upon receipt~~European, East weAsian ~~enter the results in our customer database~~ and ~~deliver~~Sub-Saharan ~~the results to the consumer by email~~African.

The results for paternity tests and Y-chromosome relationship tests and grandparent or uncle or aunt tests, are interpreted within 4 to 5 business days of the lab’s receipt of the test. Ancestry origin tests are interpreted within 21 to 28 days of receipt. Genetic predisposition test including diet and fitness testing are interpreted within 28-42 days of receipt. We typically deliver the test results to the customer by email within 1 to 4 days after our receipt. Predisposition

14Genetic predisposition testing can identify a person’s predisposition for over 70 health conditions based upon their DNA.

~~Suppliers~~Carrier Test Identification

~~We purchase our DNA~~ Carrier test ~~components~~identification ~~from~~can ~~Pro~~identify ~~Printing~~individuals ~~and~~who ~~Mailing~~carry ~~Services~~a ~~Inc.~~genetic located at 1235 Trafalgar Road, Oakville, Ontario, L6H 3P1 and assemble the products at our facilities, or we purchase finished kits previously from Pathway Genomics Lab, 4045 Sorrento Valley Boulevard, San Diego, CA 92121disorder.

~~Marketing~~Drug Response ~~Strategy~~Testing

~~Our~~Drug response ~~first~~testing ~~product~~identifies ~~sale~~uses ~~was~~a inperson’s ~~April~~DNA ofto ~~2010.~~identify Wemetabolism ~~have~~enzymes ~~not yet implemented a marketing strategy~~ and ~~all~~transporters ~~sales~~that ~~to date~~ have been ~~generated~~linked byto harmful ~~our~~reactions ~~website~~with orcommon ~~related~~medical ~~parties~~prescriptions. ~~Sales generated from our website are placed by phone order. We presently offer our paternity testing kits for purchase on our website. We offer an online shopping cart featuring all of our products.~~

Our core marketing strategy is to brand our “DNA For Family” slogan for those seeking information that can be determined by DNA testing such as kinships and ancestry and our “DNA For Health” slogan for those seeking to improve their health by DNA testing to determine disease predisposition, nutrition and fitness testing. 8

WeThe Testing ~~implemented our marketing plan in April of 2015.~~ Process

·Our DNA test kits include swabs to collect a saliva sample, detailed instructions and pre-labeled packaging to send the sample to us. Upon receipt of the sample, it is registered in our database and sent to a third party laboratory to be interpreted. All tests are interpreted by either US laboratories accredited by CLIA and CAP or Canadian laboratories accredited by the Standard Council of Canada and CAP. After interpretation, the laboratory delivers the test results to us by email. Upon receipt, we enter the results in our customer database and deliver the results to the consumer by email.

InThe results ~~April~~for ofpaternity ~~2015,~~tests weand ~~began~~Y-chromosome ~~social~~relationship ~~media~~tests ~~campaigns~~and ongrandparent ~~Twitter,~~or ~~Facebook~~uncle or aunt tests, ~~Linkedin~~are interpreted within 4 to 5 business days of the lab’s receipt of the test. Ancestry origin tests are interpreted within 21 to 28 days of receipt. Genetic predisposition test including diet and ~~other~~fitness ~~websites~~testing are interpreted within 28-42 days of receipt. We typically deliver the test results to ~~market~~the customer by email within 1 to 4 days after our ~~products;~~receipt.

·Suppliers

InWe purchase ~~May~~our ofDNA ~~2015,~~test wecomponents ~~established~~from ~~Google~~Pro ~~AdWords~~Printing and ~~search~~Mailing ~~engine~~Services ~~optimization~~Inc. ~~campaigns~~located ~~targeting~~at ~~consumers~~1235 inTrafalgar ~~Canada;~~Road, Oakville, Ontario, L6H 3P1 and assemble the products at our facilities, or we purchase finished kits previously from Pathway Genomics Lab, 4045 Sorrento Valley Boulevard, San Diego, CA 92121.

·Marketing Strategy

InOur first ~~June~~product sale was in April of ~~2015,~~2010. weWe ~~offered~~have ~~incentive~~not ~~for~~yet ~~medical~~implemented ~~practitioners,~~a ~~medical~~marketing ~~facilities~~strategy and ~~fitness~~all ~~centers~~sales to date have been generated by our website or related parties. Sales generated from our website are placed by phone order. We presently offer our paternity testing kits for purchase on our website. We offer an online shopping cart featuring all of our products.

·Our core marketing strategy is to brand our “DNA For Family” slogan for those seeking information that can be determined by DNA testing such as kinships and ancestry and our “DNA For Health” slogan for those seeking to improve their health by DNA testing to determine disease predisposition, nutrition and fitness testing.

InWe implemented ~~September~~our ofmarketing ~~2015,~~plan ~~we offered event promotions to medical offices, clinics and fitness centers~~ in ~~Canada~~April toof ~~demonstrate our products~~2015.

~~Since~~● ~~then~~In weApril ~~have been using facebook paid adverts every 2 months for selling different types~~ of ~~DNA~~2015, ~~tests.~~we Webegan ~~have made~~ social media ~~management~~campaigns ason ~~priority~~Twitter, ~~for~~Facebook, ~~the~~Linkedin ~~marketing~~and ~~plan~~other ofwebsites ~~2016. We~~to ~~promote~~market our ~~website~~products; in● ~~various~~In ~~different~~May ~~media~~of ~~platforms such as Twitter~~2015, ~~Facebook,.~~we established Google ~~Circle~~AdWords and ~~Google~~search ~~Ads. We~~engine ~~have~~optimization ~~promoted~~campaigns ~~our~~targeting ~~product~~consumers atin ~~international~~Canada; ~~events~~and ~~including~~● ~~medical mission trip to India twice a year.~~ In ~~August~~June of ~~2016~~2015, we ~~began~~offered ~~advertising~~incentive ~~our~~for ~~products~~medical atpractitioners, ~~local~~medical ~~business~~facilities ~~fairs~~and fitness centers.

WeIn September ~~also~~of ~~plan~~2015, towe ~~attract~~offered ~~medical~~event ~~practitioners~~promotions ~~and~~to ~~their~~medical ~~customers through the existing relationships of our chief executive officer~~offices, ~~president~~clinics and ~~director,~~fitness ~~Dr.~~centers ~~Barjinder~~in ~~Sohal,~~Canada ato ~~licensed~~demonstrate ~~physician, and Dr. Nitan Arora,~~ our ~~vice president and director, a chiropractic physician~~products.

We also ~~believe~~plan ~~that~~to aattract ~~marketing~~medical ~~mix~~practitioners ofand ~~social~~their ~~media,~~customers ~~email~~through ~~advertising,~~the ~~print~~existing ~~advertising~~relationships inof ~~medical~~our ~~journals~~chief ~~and~~executive ~~health/ fitness publications~~officer, president ~~internet advertising~~ and ~~medical~~director, ~~office~~Dr. ~~and~~Barjinder ~~fitness~~Sohal, ~~center~~a ~~event~~licensed ~~promotions~~physician, ~~providing information~~ and ~~sample~~Dr. ~~test~~Nitan ~~kits~~Arora, isour anvice ~~optimal~~president ~~strategy~~and todirector, ~~increase~~a ~~sales~~chiropractic physician.

15We believe that a marketing mix of social media, email advertising, print advertising in medical journals and health/ fitness publications, internet advertising and medical office and fitness center event promotions providing information and sample test kits is an optimal strategy to increase sales.

~~Raw Materials~~9

Raw materials used by us in our DNA test kits are available from a variety of suppliers. We maintain a good relationship with our suppliers and do not anticipate that any of our suppliers will terminate their relationship with us in the near term. In the event, we are unable to obtain any of our raw materials from our suppliers, we believe that we could obtain alternative sources of any raw materials from other suppliers. We do not have contracts with our suppliers and we order our raw materials on an as-needed basis. We have not experienced any material adverse effect on our business as a result of shortages of raw materials. An unexpected interruption or a shortage in supply of raw materials could adversely affect our business derived from these products. Materials

~~Research~~Raw materials used by us in our DNA test kits are available from a variety of suppliers. We maintain a good relationship with our suppliers and ~~Development~~do not anticipate that any of our suppliers will terminate their relationship with us in the near term. In the event, we are unable to obtain any of our raw materials from our suppliers, we believe that we could obtain alternative sources of any raw materials from other suppliers. We do not have contracts with our suppliers and we order our raw materials on an as-needed basis. We have not experienced any material adverse effect on our business as a result of shortages of raw materials. An unexpected interruption or a shortage in supply of raw materials could adversely affect our business derived from these products.

~~All of our research to date has been done by Dr. Barjinder Sohal, our chief executive officer, president~~ Research and director who is a licensed physician in Canada and Dr. Nitan Arora, our vice president and director, who is a licensed chiropractic physician in Canada. We have not spent any amounts on research and development in the prior two years.Development

~~Property~~All of our research to date has been done by Dr. Barjinder Sohal, our chief executive officer, president and director who is a licensed physician in Canada and Dr. Nitan Arora, our vice president and director, who is a licensed chiropractic physician in Canada. We have not spent any amounts on research and development in the prior two years.

We rent our office space at 2378 Parkhaven Boulevard, Oakville, Ontario, L6H 0E7, Canada from Navjot Nanda. This property is a lease of a 400 square foot office that is owned by Navjot Nanda, our treasurer, secretary, and director. We currently pay $1,000 per month, and occupy the premises on a month-to-month basis. Property

~~Seasonality~~We rent our office space at 2378 Parkhaven Boulevard, Oakville, Ontario, L6H 0E7, Canada from Navjot Nanda. This property is a lease of a 400 square foot office that is owned by Navjot Nanda, our treasurer, secretary, and director. We currently pay $1,000 per month, and occupy the premises on a month-to-month basis.

~~Our business is not affected by seasonal factors.~~Seasonality

~~Intellectual~~Our business ~~Property~~is not affected by seasonal factors.

We have no registered or patented intellectual property. Trademarks and trade names distinguish the various companies from each other. If customers are unable to distinguish our products from those of other companies, we could lose sales to our competitors. We do not have any registered trademarks and trade names, so we only have common law rights with respect to infractions or infringements on its products. Many subtleties exist in product descriptions, offering and names that can easily confuse customers. The name of our principal products may be found in numerous variations of the name and descriptions in various media and product labels. This presents a risk of losing potential customers looking for our products and buying someone else’s because they cannot differentiate between them.Intellectual Property

~~Overview~~We have no registered or patented intellectual property. Trademarks and trade names distinguish the various companies from each other. If customers are unable to distinguish our products from those of other companies, we could lose sales to our competitors. We do not have any registered trademarks and trade names, so we only have common law rights with respect to infractions or infringements on its products. Many subtleties exist in product descriptions, offering and names that can easily confuse customers. The name of our principal products may be found in numerous variations of the name and descriptions in various media and product labels. This presents a risk of losing potential customers looking for our products and buying someone else’s because they cannot differentiate between them.

~~DNA Testing Centers, Corp., together with our wholly-owned subsidiary, DNA Centers of Canada, Ltd., are collectively referred to herein as the “Company,” “us” or “we.”~~ Overview

WeDNA Testing ~~are~~Centers, ~~incorporated in the State of Florida on July 3~~Corp., ~~2014,~~together towith ~~acquire~~ our wholly -owned subsidiary, DNA Centers of Canada, Ltd., aare ~~Canadian~~collectively ~~corporation~~referred ~~formed~~to onherein as ~~April~~the 6“Company,” ~~2009,~~“us” toor ~~distribute~~“we.”

16We were incorporated in the State of Florida on July 3, 2014, to acquire our wholly owned subsidiary DNA Centers of Canada, Ltd., a Canadian corporation formed on April 6, 2009, to distribute DNA testing products to consumers and medical practitioners in Canada.

We currently sell our DNA ~~testing~~test ~~products~~kits directly to ~~consumers~~our customers. Our customers are both individuals and medical practitioners. inOur DNA ~~Canada~~testing kits are sold directly to customers who place orders by telephone.

We currently sell our DNA test kits directly to our customers. Our customers are both individuals and medical practitioners. Our DNA testing kits are sold directly to customers who place orders by telephone.10

Going Concern

As reflected in the accompanying interim consolidated financial statements, we have an accumulated deficit of $~~261~~326,~~166~~242 ~~as of September 30, 2016,~~ and ~~realized~~working capital ~~negative~~deficit ~~cash~~of ~~used by operations totaling~~ $51114,~~139~~947 ~~for~~as ~~the~~of ~~period~~June ~~ended September~~ 30, ~~2016~~2017. We currently have limited liquidity, and has not completed its efforts to establish a stabilized source of revenues sufficient to cover operating costs over an extended period of time. This raises substantial doubt about its ability to continue as a going concern. Our ability to continue as a going concern is dependent on our ability to raise additional capital and implement its business plan. The interim consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.

Management believes that actions presently being taken to obtain additional funding and implement its strategic plans provide the opportunity for us to continue as a going concern.

Results of Operations

Three Months Ended ~~September~~June 30, ~~2016~~2017 Compared to the Three Months Ended ~~September~~June 30, ~~2015~~2016

For the three months ended ~~September~~June 30, ~~2016~~2017, we had revenues of $1116,~~503~~759 compared to $45,~~564~~871 for the three months ended ~~September~~June 30, ~~2015~~2016. The increase in revenues was due to increased online advertising which led to an increase in sales.

Operating expenses decreased to $1613,~~091~~868 for the three months ended ~~September~~June 30, ~~2016~~2017 compared to $3079,~~028~~398 for the three months ended ~~September~~June 30, 2016, ~~2015~~mainly due to the decrease in ~~the~~ ~~amount~~consulting ~~allotted for testing~~ fees ~~and cost allotted for other operating expenses~~.

We had a net loss of $41,~~588~~905 for the three months ended ~~September~~June 30, ~~2016~~2017, which was less than the net loss of $2577,~~464~~123 for the three month ended ~~September~~June 30, ~~2015~~2016. The decrease in net loss mainly resulted from the ~~decrease~~increase in ~~net~~gross ~~operating~~profit ~~expenses~~and decrease in consulting fees.

The following table summarizes key items of comparison and their related increase (decrease) for the three-month periods ended ~~September~~ June 30, ~~2016~~2017 and ~~2015~~2016:

	Three Months Ended September 30, 2016		Three Months Ended September 30, 2015
	Three Months Ended June 30, 2017			Three Months Ended June 30, 2016
Revenues	$~~11,503~~	16,759	~~$4,564~~	$	5,871
Testing Fees	12,626		16,827
Direct costs		4,796			3,596
Other Operating Expenses	3,465		13,201
Operating Expenses		13,868			79,398
Stock-based Compensation	Nil		Nil
Net income (loss)	$	(1,905	)	$	(77,123	)
Net loss	$4,588		$25,464

17Six Months Ended June 30, 2017 Compared to the Six Months Ended June 30, 2016

~~Nine~~For the ~~Months~~six ~~Ended~~months ~~September~~ended June 30, ~~2016~~2017, ~~Compared~~our company had revenues of $32,476 compared to $9,351 for the ~~Nine~~six ~~Months~~months ~~Ended~~ended ~~September~~June 30, ~~2015~~2016. The increase in revenues was due to an increase in online advertising which led to an increase in sales.

~~For~~Operating expenses ~~the~~decreased ~~nine~~to ~~months ended September 30~~$28,793 ~~2016,~~for ~~our~~the ~~company~~six ~~had~~months ~~revenues~~ended ofJune ~~$20~~30,~~854~~ 2017 compared to $1497,~~964~~642 for the ~~nine~~six months ended ~~September~~June 30, ~~2015.~~2016, mainly ~~The increase in revenues was~~ due to anthe ~~increase~~decrease in ~~online~~consulting ~~advertising which led to an increase in sales~~fees.

Operating expenses increased to $120,025 for the nine months ended September 30, 2016 compared to $113,345 for the nine months ended September 30, 2015, due to the increase in testing fees, and stock based compensation.11

We had a net loss of $992,~~171~~960 for the ~~nine~~six months ended ~~September~~June 30, ~~2016~~2017, which was ~~more~~less than the net loss of $9894,~~381~~583 for the ~~nine~~six months ended ~~September~~June 30, ~~2015~~2016. Our ~~increased~~decreased net loss resulted from ~~increases~~the increase in ~~testing~~gross ~~fees,~~profit and ~~stock~~a ~~based~~decrease ~~compensations~~in consulting fees.

The following table summarizes key items of comparison and their related increase (decrease) for the ~~nine~~six month periods ended ~~September~~ June 30, ~~2016~~2017 and ~~2015~~2016:

	Nine Months Ended September 30, 2016		Nine Months Ended September 30, 2015
	Six Months Ended June 30, 2017			Six Months Ended June 30, 2016
Revenues	$~~20,854~~	32,476	~~$14,964~~	$	9,351
Testing Fees	37,439		33,650
Direct costs		6,643			6,292
Other operating Expenses	30,086		79,695
Operating expenses		28,793			97,642
Stock-based Compensation	52,500		Nil
Net income (loss)	$	(2,960	)	$	(94,583	)
Net loss	$99,171		$98,381

Liquidity and Capital Resources

Our balance sheet as of ~~September~~June 30, ~~2016~~2017 reflects current assets of $89,~~259~~749. We had cash ~~and cash equivalents~~ in the amount of $37,~~034~~505 which is insufficient to carry out our stated plan of operation for the next twelve months.

As of ~~September~~June 30, ~~2016~~2017, our company had accumulated losses of $~~261~~326,~~166~~242 since inception and had a working capital deficit of $54118,~~040~~694. These factors raise substantial doubt regarding our company’s ability to continue as a going concern. The continuation of our company as a going concern is dependent upon financial support from its stockholders, the ability of our company to obtain necessary equity financing to continue operations, and the attainment of profitable operations. The full and timely development and implementation of our business plan and growth strategy will require significant additional resources, and our company may not be able to obtain the funding necessary to implement its growth strategy on acceptable terms or at all.

18An inability to obtain such funding could slow down or prevent our company from further development of our business. Our company intends to explore additional options to secure sources of capital, including the issuance of debt, and equity, including preferred equity securities or other equity securities. Our company does not have commitments from any third parties to provide additional financing. Our company might not succeed in raising additional equity capital or in negotiating and obtaining additional and acceptable financing when it needs it or at all. Our company’s ability to obtain additional capital will also depend on market conditions, national and global economies and other factors beyond its control. We cannot assure you that our company will be able to implement or capitalize on various financing alternatives or otherwise obtain required capital, the need for which is substantial given its operating loss history and its business and development plan. The terms of any future debt or equity funding that our company may obtain in the future may be unfavorable to our company and to its stockholders.

An inability to obtain such funding could slow down or prevent our company from further development of our business. Our company intends to explore additional options to secure sources of capital, including the issuance of debt, and equity, including preferred equity securities or other equity securities. Our company does not have commitments from any third parties to provide additional financing. Our company might not succeed in raising additional equity capital or in negotiating and obtaining additional and acceptable financing when it needs it or at all. Our company’s ability to obtain additional capital will also depend on market conditions, national and global economies and other factors beyond its control. We cannot assure you that our company will be able to implement or capitalize on various financing alternatives or otherwise obtain required capital, the need for which is substantial given its operating loss history and its business and development plan. The terms of any future debt or equity funding that our company may obtain in the future may be unfavorable to our company and to its stockholders.Working Capital

Working Capital

	At June 30, 2017			At December 31, 2016
Current assets	$	9,749		$	6,188
Current liabilities		128,443			119,541
Working capital (deficit)	$	(118,694	)	$	(113,353	)

	At September 30, 2016		At December 31, 2015
Current assets	$	8,259	$	361
Current liabilities		62,299		6,698
Working capital (deficit)	$	(54,040)	$	(6,337)

We anticipate generating losses and, therefore, may be unable to continue operations further in the future.

~~We anticipate generating losses and, therefore, may be unable to continue operations further in the future.~~12

Cash Flows

	Nine Months Ended
	Six Months Ended
	September 30,
	June 30,
	2016			2015
	2017			2016
Net cash used in operating activities	$	(516,~~139)~~172	)	$	(9742,~~721)~~321	)
Net cash provided by investing activities		Nil			Nil
Net cash provided by financing activities		559,~~404~~327			4847,~~867~~213
Foreign currency transaction		(1,438)			(7,235)
Effect of foreign exchange rate changes on cash		572			(2,196	)
Net increase (decrease) in cash during period	$	2,827		$	(56,088)
Net increase in cash during period	$	3,727		$	2,696

Operating Activities

Net cash used in operating activities during the ~~nine~~six months ended ~~September~~June 30, ~~2016~~2017 was $516,~~139~~172, a decrease from the $9742,~~721~~321 net cash used during the ~~nine~~six months ended ~~September~~June 30, ~~2015~~2016.

Investing Activities

Our company had no investing activities during the ~~nine~~six months ended ~~September~~June 30, ~~2016~~2017 and ~~September 30, 2015~~2016.

19Financing Activities

~~Financing~~Cash provided ~~Activities~~by financing activities during the six months ended June 30, 2017 was $9,327 as compared to $47,213 during the six months ended June 30, 2016.

~~Cash provided by financing activities during the nine months ended September 30, 2016 was $55,404 as compared to $48,867 during the nine months ended September 30, 2015.~~Future Financings

~~Future~~We anticipate ~~Financings~~that we will have to generate enough revenue or enter into additional debt or equity financings to have enough cash to sustain operations for at least a year. However, we cannot make any assurance that we will be successful in generating enough revenue or obtain additional financings to sustain operations. Moreover, our independent auditors stated in their report on our audited financial statements that they have substantial doubt that we will be able to continue as a going concern without further financing.

WeManagement may ~~anticipate~~decide, ~~that~~based weon ~~will~~market ~~have~~conditions, to ~~generate~~seek ~~enough~~future ~~revenue~~private orplacements ~~enter~~if ~~into~~management ~~additional~~believes ~~debt~~such orprivate ~~equity~~placements ~~financings~~are ~~to have enough cash to sustain operations for at least a year. However, we cannot make any assurance that we will be successful~~ in the ~~generating~~best ~~enough~~interests ~~revenue~~of ~~or obtain additional financings to sustain operations. Moreover,~~ our ~~independent auditors stated in their report on our audited financial statements that they have substantial doubt that we will be able to continue as a going concern without further financing~~company.

~~Management~~Off-Balance Sheet ~~may decide, based on market conditions, to seek future private placements if management believes such private placements are in the best interests of our company.~~Arrangements

~~Off~~We have no off-~~Balance~~balance ~~Sheet~~sheet ~~Arrangements~~arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to stockholders.

WeCritical Accounting ~~have~~Policies noand off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to stockholders.Estimates

~~Critical~~Use of ~~Accounting Policies and Estimates~~estimates

~~Use~~The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States necessarily requires management to make estimates and assumptions that affect the amounts reported in the financial statements. We regularly evaluate estimates and judgment based on historical experience and other relevant facts and circumstances. Actual results could differ from those estimates.

The preparation of financial statements in conformity with accounting principles generally accepted in the United States necessarily requires management to make estimates and assumptions that affect the amounts reported in the financial statements. We regularly evaluate estimates and judgment based on historical experience and other relevant facts and circumstances. Actual results could differ from those estimates.13

~~Cash and cash equivalents~~Revenue recognition

~~Cash~~The Company ~~equivalents~~derives ~~are~~revenue ~~highly~~from ~~liquid~~the ~~investments~~sale ~~with~~of DNA diagnostic testing kits in relation to analyzing and monitoring an ~~original~~individual’s genetic ~~maturity~~makeup. In accordance with ASC 605, “Revenue Recognition”, revenue is recognized when persuasive evidence of ~~three~~an ~~months~~arrangement exists, services have been rendered, the sale price is fixed or ~~less~~determinable, and collectability is reasonably assured.

~~Revenue~~Recent Accounting ~~recognition~~Pronouncements

~~Revenue~~We do isnot ~~recognized~~expect ~~when~~the ~~persuasive~~adoption ~~evidence~~ of anrecently ~~arrangement~~issued ~~exists,~~accounting ~~services~~pronouncements to have ~~been~~a ~~rendered,~~significant ~~the~~impact ~~sales~~on ~~price~~our isresults ~~fixed~~of ~~or determinable~~operations, financial ~~and~~position ~~collectability~~or iscash ~~reasonably assured~~flow. ~~This occurs only when the services are rendered.~~

20Item 3. Quantitative and Qualitative Disclosures About Market Risk

~~Income~~As a ~~taxes~~“smaller reporting company”, we are not required to provide the information required by this Item.

Deferred tax asset and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basesItem 4. ~~These~~Controls ~~assets~~ and ~~liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which the temporary differences are expected to reserve.~~Procedures

WeManagement’s Report ~~have~~on ~~net~~Disclosure ~~operating~~Controls ~~loss~~and carry-forwards available to reduce future taxable income. Future tax benefits for these operating loss carry-forwards are recognized to the extent that realization of these benefits is considered more likely than not. To the extent that we will not realize a future tax benefit, a valuation allowance is established.Procedures

~~Financial~~We maintain ~~instrument~~disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our president (our principal executive officer, principal financial officer and principal accounting officer) to allow for timely decisions regarding required disclosure.

~~The~~As of ~~carrying~~the ~~amount~~end of our ~~financial~~quarter ~~instruments~~covered by this report, ~~consisting~~we ofcarried ~~cash~~out ~~equivalents~~an evaluation, ~~accounts~~under the supervision and ~~notes~~with ~~receivable~~the participation of our president (our principal executive officer, ~~accounts~~principal financial officer and ~~notes~~principal ~~payable~~accounting officer), ~~short-term~~of ~~borrowings~~the effectiveness of the design and ~~certain~~operation ~~other~~of ~~liabilities~~our disclosure controls and procedures. Based on the foregoing, ~~approximates~~our ~~fair~~president ~~value~~(our ~~since~~principal executive officer, principal financial officer and principal accounting officer) concluded that our disclosure controls and procedures were not effective in providing reasonable assurance in the ~~stated~~reliability ~~rate~~of our reports as of ~~interest~~the ~~approximates~~end aof ~~market~~the ~~rate~~period covered by this quarterly report. This was due to deficiencies that existed in the design or operation of ~~interest~~our internal control over financial reporting that adversely affected our internal controls and that may be considered to be material weaknesses.

~~Foreign~~The matters ~~currency~~involving ~~translation~~internal control over financial reporting that our management considered to be material weaknesses under the standards of the Public Company Accounting Oversight Board were: (1) lack of a functioning audit committee due to a lack of a majority of independent members and a lack of a majority of outside directors on our board of directors, resulting in ineffective oversight in the establishment and monitoring of required internal controls and procedures; (2) inadequate segregation of duties consistent with control objectives of having segregation of the initiation of transactions, the recording of transactions and the custody of assets; and (3) ineffective controls over period end financial disclosure and reporting processes. The aforementioned material weaknesses were identified by our president (our principal executive officer, principal financial officer and principal accounting officer) in connection with the review of our consolidated financial statements as of June 30, 2017.

Assets and liabilities of Canadian operations are translated into United States dollar equivalents using the exchange rate in effect at the balance sheet date. Revenue and expenses are translated using the average exchange rates during each period. Adjustments resulting from the process of translating foreign functional currency financial statements into U.S. dollars are included in accumulated other comprehensive income in common shareholders' equity. Foreign currency transaction gain and losses are included in the current earnings and totaled $1,438 and $6,924 for the period ended September 30, 2016 and December 31, 2015, respectively.14

~~Property~~To address the material weaknesses set forth in items (2) and ~~equipment~~(3) discussed above, management performed additional analyses and other procedures to ensure that the consolidated financial statements included herein fairly present, in all material respects, our financial position, results of operations, and cash flows for the periods presented.

~~Property~~This quarterly ~~and~~report ~~equipment~~does isnot ~~recorded~~include atan ~~cost. Major~~attestation ~~additions~~report ~~and improvements are capitalized and depreciated over their estimated useful lives. Depreciation~~ of ~~property~~our ~~and~~company’s ~~equipment~~independent isregistered ~~determined~~public ~~using~~accounting ~~the~~firm ~~straight-line~~regarding internal ~~method~~control over ~~the~~financial ~~useful~~reporting. ~~life,~~Management’s ~~which~~report iswas ~~estimated~~not atsubject ~~ten~~to ~~years. Gains~~attestation orby ~~losses~~our oncompany’s ~~the~~independent registered ~~sale~~public oraccounting ~~disposal~~firm ofpursuant ~~property~~to ~~and equipment are included in~~ the ~~statements~~rules of ~~operations.~~the ~~Maintenance~~SEC ~~and repairs~~ that dopermit ~~not~~our ~~extend~~company ~~the~~to ~~useful~~provide ~~life~~only of the ~~assets~~management’s report ~~are~~in ~~expensed~~this asquarterly ~~incurred~~report.

~~Impairment~~Changes in ofInternal ~~Long-Lived~~Control ~~Assets~~Over Financial Reporting

~~Long-lived~~During the ~~assets,~~period ~~including~~covered ~~property~~by ~~and~~this ~~equipment~~report ~~are~~there ~~reviewed~~were ~~for~~no ~~impairment whenever events or~~ changes in ~~circumstances~~our ~~indicate~~internal ~~that~~control ~~the~~over ~~carrying~~financial ~~amount~~reporting ~~may~~that ~~not~~materially beaffected, or ~~recoverable.~~are ~~The~~reasonably ~~evaluation~~likely ~~of recoverability is performed using undiscounted estimated net cash flows generated by the related asset. If an asset is deemed~~ to bematerially ~~impaired~~affect, ~~the~~our ~~amount~~internal ofcontrol ~~impairment~~over isfinancial ~~determined as the amount by which the net carrying value exceeds discounted estimated cash flows~~reporting.

21PART II – OTHER INFORMATION

~~Basic~~Item 1. ~~and~~Legal ~~diluted net income (loss) per share~~Proceedings

~~Basic~~We know ~~net~~of ~~income~~no ~~per~~material, ~~common~~existing ~~share~~or ispending ~~computed~~legal byproceedings ~~dividing~~against ~~net~~our ~~income~~company, ~~applicable~~nor toare ~~common~~we ~~stockholders~~involved byas ~~the~~a ~~weighted~~plaintiff ~~average~~in ~~number~~any ofmaterial proceeding ~~common~~or ~~shares~~pending ~~outstanding during the period~~litigation. ~~Diluted~~There ~~net~~are ~~income~~no ~~per~~proceedings ~~share~~in iswhich ~~determined~~our bydirector, ~~dividing~~officer ~~the~~or ~~net~~any ~~income~~affiliates, byor ~~the~~any ~~sum~~registered or ofbeneficial ~~(1) the weighted average number of common shares outstanding and (2) if not anti-dilutive~~shareholder, ~~the~~is ~~effect~~an ofadverse ~~stock~~party ~~awards~~or ~~determined~~has ~~utilizing~~a ~~the~~material ~~treasury~~interest ~~stock~~adverse ~~method.~~to ~~The~~our ~~dilutive effect of the outstanding awards for the period ended September 30, 2016 and December 31, 2015 was -0- shares~~interest.

~~Recent~~Item 1A. ~~Accounting~~Risk ~~Pronouncements~~Factors

WeAs a do“smaller ~~not~~reporting ~~expect~~company”, ~~the~~we ~~adoption~~are ofnot ~~recently~~required ~~issued accounting pronouncements~~ to ~~have~~provide athe ~~significant~~information ~~impact~~required onby ~~our~~this ~~results of operations, financial position or cash flow~~Item.

Item 3 2. ~~Quantitative~~Unregistered ~~and~~Sales ~~Qualitative~~of ~~Disclosures~~Equity ~~About~~Securities ~~Market~~and ~~Risk~~Use of Proceeds

~~As a “smaller reporting company”, we are not required to provide the information required by this Item~~None.

Item 4 3. ~~Controls~~Defaults ~~and~~Upon ~~Procedures~~Senior Securities

~~Management’s Report on Disclosure Controls and Procedures~~None.

WeItem 4. ~~maintain~~Mine ~~disclosure~~Safety controls and procedures that are designed to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our president (our principal executive officer, principal financial officer and principal accounting officer) to allow for timely decisions regarding required disclosure.Disclosures

As of the end of our quarter covered by this report, we carried out an evaluation, under the supervision and with the participation of our president (our principal executive officer, principal financial officer and principal accounting officer), of the effectiveness of the design and operation of our disclosure controls and proceduresNot Applicable. Based on the foregoing, our president (our principal executive officer, principal financial officer and principal accounting officer) concluded that our disclosure controls and procedures were not effective in providing reasonable assurance in the reliability of our reports as of the end of the period covered by this quarterly report. This was due to deficiencies that existed in the design or operation of our internal control over financial reporting that adversely affected our internal controls and that may be considered to be material weaknesses.

22Item 5. Other Information

The matters involving internal control over financial reporting that our management considered to be material weaknesses under the standards of the Public Company Accounting Oversight Board were: (1) lack of a functioning audit committee due to a lack of a majority of independent members and a lack of a majority of outside directors on our board of directors, resulting in ineffective oversight in the establishment and monitoring of required internal controls and procedures; (2) inadequate segregation of duties consistent with control objectives of having segregation of the initiation of transactions, the recording of transactions and the custody of assets; and (3) ineffective controls over period end financial disclosure and reporting processesNone. The aforementioned material weaknesses were identified by our president (our principal executive officer, principal financial officer and principal accounting officer) in connection with the review of our financial statements as of September 30, 2016.

To address the material weaknesses set forth in items (2) and (3) discussed above, management performed additional analyses and other procedures to ensure that the financial statements included herein fairly present, in all material respects, our financial position, results of operations and cash flows for the periods presented.15

~~This quarterly report does not include an attestation report of our company’s independent registered public accounting firm regarding internal control over financial reporting~~Item 6. Management’s report was not subject to attestation by our company’s independent registered public accounting firm pursuant to the rules of the SEC that permit our company to provide only the management’s report in this quarterly report.Exhibits

Changes in Internal Control Over Financial Reporting

Exhibit Number		Description
(3)		Articles of Incorporation; Bylaws
3.1		Articles of Incorporation (incorporated by reference to our Registration Statement on Form S-1 filed on October 24, 2014).
3.2		Bylaws (incorporated by reference to our Registration Statement on Form S-1 filed on October 24, 2014).
(10)		Material Contracts
10.1		Lease Agreement between Testing Centers Corp and Navjot Nanda (incorporated by reference to our Registration Statement on Form S-1 filed on October 24, 2014).
10.2		Employment Agreement between DNA Testing Centers Corp and Dr. Barjinder Sohal (incorporated by reference to our Registration Statement on Form S-1 filed on October 24, 2014).
10.3		Employment Agreement between DNA Testing Centers Corp and Dr. Nitan Arora (incorporated by reference to our Registration Statement on Form S-1/A filed on October 24, 2014).
10.4		Employment Agreement between DNA Testing Centers Corp and Navjot Nanda (incorporated by reference to our Registration Statement on Form S-1 filed on October 24, 2014).
10.5		Agreement between DNA Testing Centers Corp and DNA Testing Centers of Canada, Ltd. (incorporated by reference to our Registration Statement on Form S-1 filed on January 28, 2015).
10.6		Amending Employment Agreement between DNA Testing Centers Corp and Dr. Barjinder Sohal (incorporated by reference to our Registration Statement on Form S-1/A #5 filed on September 17, 2015).
10.7		Amending Employment Agreement between DNA Testing Centers Corp and Dr. Nitan Arora (incorporated by reference to our Registration Statement on Form S-1/A #5 filed on September 17, 2015).
10.8		Amending Employment Agreement between DNA Testing Centers Corp and Navjot Nanda (incorporated by reference to our Registration Statement on Form S-1/A #5 filed on September 17, 2015).
(21)		Subsidiaries
21.1		DNA Testing Centers of Canada, Ltd., a company formed pursuant to the laws of Alberta (wholly owned).
(31)		Rule 13a-14(a) / 15d-14(a) Certifications
31.1*		Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 of the Principal Executive Officer
31.2*		Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 of the Principal Financial Officer and Principal Accounting Officer
(32)		Section 1350 Certifications
32.1*		Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 of the Principal Executive Officer
32.2*		Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 of the Principal Financial Officer and Principal Accounting Officer
101*		Interactive Data File
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Document
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		XBRL Taxonomy Extension Label Linkbase Document
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

~~During~~* ~~the~~Filed period covered by this report there were no changes in our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reportingherewith.

2316

~~PART II – OTHER INFORMATION~~SIGNATURES

~~Item~~In accordance 1.with ~~Legal~~Section ~~Proceedings~~13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

We know of no material, existing or pending legal proceedings against our company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which our director, officer or any affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our interest.

	DNA TESTING CENTERS, CORP.

Date: July 9, 2019	By:	/s/ Barjinder Sohal
		Barjinder Sohal
		President, Chief Executive Officer and Director (Principal Executive Officer)

Item 1A. Risk Factors

Date: July 9, 2019

By:

/s/ Nitan Arora

Nitan Arora

Vice President, Chief Financial Officer and Director

(Principal Financial Officer and Principal Accounting Officer)

~~As a “smaller reporting company”, we are not required to provide the information required by this Item.~~17

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not Applicable.

Item 5. Other Information

None.

Item 6. Exhibits

Exhibit Number			Description
(3)			Articles of Incorporation; Bylaws
3.1			Articles of Incorporation (incorporated by reference to our Registration Statement on Form S-1 filed on October 24, 2014).
3.2			Bylaws (incorporated by reference to our Registration Statement on Form S-1 filed on October 24, 2014).
(10)			Material Contracts
10.1			Lease Agreement between Testing Centers Corp and Navjot Nanda (incorporated by reference to our Registration Statement on Form S-1 filed on October 24, 2014).
10.2			Employment Agreement between DNA Testing Centers Corp and Dr. Barjinder Sohal (incorporated by reference to our Registration Statement on Form S-1 filed on October 24, 2014).
10.3			Employment Agreement between DNA Testing Centers Corp and Dr. Nitan Arora (incorporated by reference to our Registration Statement on Form S-1/A filed on October 24, 2014).
10.4			Employment Agreement between DNA Testing Centers Corp and Navjot Nanda (incorporated by reference to our Registration Statement on Form S-1 filed on October 24, 2014).
10.5			Agreement between DNA Testing Centers Corp and DNA Testing Centers of Canada, Ltd. (incorporated by reference to our Registration Statement on Form S-1 filed on January 28, 2015).
10.6			Amending Employment Agreement between DNA Testing Centers Corp and Dr. Barjinder Sohal (incorporated by reference to our Registration Statement on Form S-1/A #5 filed on September 17, 2015).
10.7			Amending Employment Agreement between DNA Testing Centers Corp and Dr. Nitan Arora (incorporated by reference to our Registration Statement on Form S-1/A #5 filed on September 17, 2015).
10.8			Amending Employment Agreement between DNA Testing Centers Corp and Navjot Nanda (incorporated by reference to our Registration Statement on Form S-1/A #5 filed on September 17, 2015).
(21)			Subsidiaries
21.1			DNA Testing Centers of Canada, Ltd., a company formed pursuant to the laws of Alberta (wholly owned).
(31)			Rule 13a-14(a) / 15d-14(a) Certifications
31.1*			Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 of the Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer
(32)			Section 1350 Certifications
32.1*			Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 of the Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer
101*			Interactive Data File
101.INS			XBRL Instance Document
101.SCH			XBRL Taxonomy Extension Schema Document
101.CAL			XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF			XBRL Taxonomy Extension Definition Linkbase Document
101.LAB			XBRL Taxonomy Extension Label Linkbase Document
101.PRE			XBRL Taxonomy Extension Presentation Linkbase Document
	*	Filed herewith.

SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		DNA TESTING CENTERS, CORP.
Date: December 6, 2016	By:	/s/Barjinder Sohal
		Barjinder Sohal
		President, Chief Executive Officer and Director (Principal Executive Officer)

Date: December 6, 2016	By:	/s/Nitan Arora
		Nitan Arora
		Vice President, Chief Financial Officer and Director (Principal Financial Officer and Principal Accounting Officer)

Filing Compare · DNA Testing Centers Corp